Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

Stock Information for Aligos Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aligos Therapeutics Inc.

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
Aligos Therapeutics to Present at Upcoming Investor Conferences
Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.